Levels of anti-Müllerian hormone (AMH) may not correlate with ovarian reserve in patients with breast cancer, suggests a study presented at ESHRE 2018, thus raising questions on the utility of AMH testing before hormonal stimulation in fertility preservation for women with breast cancer.
Chemotherapy may be less damaging to fertility of female lymphoma patients who are of a younger age than those who are older, even in the case of an alkylating regimen, suggests a study presented at ESHRE 2018.
The increased risk of prostate cancer, particularly early-onset prostate cancer, among subfertile men who undergo intracytoplasmic sperm injection (ICSI) does not appear to be due to the procedure, according to a nationwide, registry-based study from Sweden.
Tubal flushing with oil-based contrast medium at hysterosalpingography (HSG) leads to a higher ongoing pregnancy rate beyond the previously reported results at 6 months, with significantly shorter time to ongoing pregnancy than flushing with water-based contrast, according to a study presented at ESHRE 2018.
Dual triggering with a gonadotropin-releasing hormone (GnRH) agonist and human chorionic gonadotropin (hCG) may increase the number of oocytes among women undergoing in vitro fertilization (IVF), according to a study presented at ESHRE 2018.
Endometrial scratching prior to in vitro fertilization (IVF) failed to improve live birth rates in the PIP* study, challenging a practice currently embraced by gynaecologists to boost the chances of embryo implantation in subfertile women.
Nonvitamin K antagonist oral anticoagulants (NOACs) appear to confer more clinical benefits to elderly patients with atrial fibrillation (AF) than vitamin K antagonist anticoagulants (VKAs), suggests a study, adding that this is primarily driven by the lower rates of major bleeding.
In patients with atrial fibrillation (AF) naïve to oral anticoagulants (OACs), standard-dose nonvitamin K antagonist OACs (NOACs) provides better survival benefits than warfarin, a recent meta-analysis has shown.
Use of diclofenac, a traditional nonsteroidal anti-inflammatory drug (NSAID) with cyclo-oxygenase-2 (COX-2) selectivity similar to COX-2 inhibitors, is associated with higher cardiovascular health risk compared with nonuse, paracetamol use and use of other traditional NSAIDs, a recent study has shown.